World News: 14:44 GMT Friday 12th July 2019. [Research and Markets via Globe Newswire via SPi World News]
Dublin, July 12, 2019 (GLOBE NEWSWIRE) -- The report has been added to offering. The global aminoglycosides market size is expected to witness a growth of over 4.3% CAGR over the forecast period, owing to the increasing burden of animal disease outbreaks leading to high utilization of antibiotics.Moreover, this class of antibiotics is found to be effective even when bacterial inoculum is large, and are frequently used as a second line of defense against basic infection resistant to basic antibacterials.Additionally, reduction in the prescription rate of aminoglycoside antibiotics due to side effects associated with the usage of these drugs that include severe ototoxicity, nephrotoxicity, and neuromuscular blockade is expected to affect the market growth negatively.Neomycin, streptomycin, gentamicin, kanamycin, tobramycin, amikacin, and others are included in the product categorization of aminoglycosides. Streptomycin is a first level antibacterial used for the treatment of tuberculosis. Aminoglycosides used in the treatment of MDR-TB include kanamycin capreomycin and amikacin.Gentamicin is the agent of choice for major bacterial infections amongst others. Tobramycin has been found to be slightly more effective against Pseudomonas aeruginosa infections. Amikacin and gentamicin find maximum usage in veterinary medicine. Gentamicin is indicated in perinatal complications, sepsis, acute/chronic renal disease, labor or neonatal complications, diabetes, and UTI/pyelonephritis.Gentamicin forms the first line of treatment for many disorders in both developing and developed markets. Its usage is particularly high in developing regions where older gentamicin is a cost-effective and efficacious drug for many infectious diseases. Thus, its demand is consistently growing for a range of bacterial infection related diseases, with several players using it in combinations.Geographically the aminoglycoside market is classified into North America, South America, Europe, Asia Pacific, and Middle East & Africa. North America dominates the global aminoglycoside market in terms of value due to increasing incidence of bacterial infections.The growing demand for early-phase diagnosis and treatment of infectious diseases is expected to drive the growth of the aminoglycoside market in North America. According to the 2017 data published by the Centres for Disease Control & Prevention (CDC), in 2016 the total approximate number of visits in the US, to physician offices for infectious diseases was 16.8 million. The increasing incidence rate and high patient-visit volume for infectious diseases is the primary driver for North America's largest share in Aminoglycoside marketEurope is the second largest market for aminoglycoside in terms of value as there are favorable government policies regarding health care infrastructure and awareness of the population.The market studied is composed of a large number of players and includes both small and large pharmaceutical manufacturers. Additionally, the increasing antibiotic resistance has prompted many early-stage biotechnology enterprises to enter this market. The expiry of patent exclusivity has led to large scale generic manufacturing of aminoglycosides, particularly in the developing region of Asia-Pacific. 1.1 Study Deliverables1.2 Study Assumptions1.3 Scope of the Study4.1 Market Overview4.2 Market Drivers4.2.1 Incurable Status of the Disease4.2.2 Global increase in Aging Population4.2.3 Increasing Prevalence of Brain Disorders4.3 Market Restraints4.3.1 Adverse and Toxic Reactions Associated with Aminoglycosides4.4 Porter's Five Force Analysis4.4.1 Threat of New Entrants4.4.2 Bargaining Power of Buyers/Consumers4.4.3 Bargaining Power of Suppliers4.4.4 Threat of Substitute Products4.4.5 Intensity of Competitive Rivalry5.1 Product5.1.1 Neomycin5.1.2 Tobramycin5.1.3 Gentamicin5.1.4 Amikacin5.1.5 Paromomycin5.1.6 Streptomycin5.1.7 Kanamycin5.1.8 Other Aminoglycosides5.2 Route of Administration5.2.1 Parenteral5.2.2 Intra-mammary5.2.3 Topical5.2.4 Oral5.3 Application5.3.1 Veterinary5.3.2 Skin Infection5.3.3 Respiratory Diseases5.3.4 UTI & Pelvic Diseases5.3.5 Other Diseases5.4 Geography5.4.1 North America18.104.22.168 US22.214.171.124 Canada126.96.36.199 Mexico5.4.2 Europe188.8.131.52 Germany184.108.40.206 UK220.127.116.11 France18.104.22.168 Italy22.214.171.124 Spain126.96.36.199 Rest of Europe5.4.3 Asia-Pacific188.8.131.52 China184.108.40.206 Japan220.127.116.11 India18.104.22.168 Australia22.214.171.124 South Korea126.96.36.199 Rest of Asia-Pacific5.4.4 Middle East and Africa188.8.131.52 GCC184.108.40.206 South Africa220.127.116.11 Rest of Middle East and Africa5.4.5 South America18.104.22.168 Brazil22.214.171.124 Argentina126.96.36.199 Rest of South America6.1 Company Profiles6.1.1 Alfasan International B.V.6.1.2 Hangzhou Uniwise International Co. Ltd.6.1.3 HuvePharma6.1.4 Jiangxi Bolai Pharmacy Co. Ltd.6.1.5 Kremoint Pharma Pvt. Ltd.6.1.6 Medico Remedies Pvt. Ltd.6.1.7 Medson Pharmaceuticals6.1.8 Vega Pharma Ltd.6.1.9 Xian Wison Biological Technology Co. Ltd.6.1.10 Yi Chang Veterinary Medicine Factory For more information about this report visit
Research and Markets also offers services providing focused, comprehensive and tailored research.
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Infectious Disease Testing
Globe Newswire: 14:44 GMT Friday 12th July 2019
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.